Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2018

01-07-2018 | Breast Oncology

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?

Authors: Debora de Melo Gagliato, MD, Mariana Chavez-MacGregor, MD, MSc

Published in: Annals of Surgical Oncology | Issue 7/2018

Login to get access

Excerpt

Use of adjuvant chemotherapy plays a crucial role in improving the outcomes of breast cancer (BC) patients.1,2 In recent years, delays in administration of adjuvant chemotherapy have been associated with detrimental outcomes. The impact on outcomes is of significant magnitude, thus timeliness in chemotherapy administration has been proposed as a quality metric. Several studies have consistently identified that a delay in time to adjuvant chemotherapy (TTC) after definitive breast surgery was associated with adverse outcomes; patients receiving adjuvant chemotherapy 90 days after definitive breast surgery have worse overall and breast cancer-specific survival.3,4 Of particular relevance is that the detrimental impact of such delays seems to be greater among patients with more advanced stages and among those with highly proliferative tumors, particularly patients with triple-negative breast cancer (TNBC).5 …
Literature
1.
2.
Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44.CrossRef
3.
Lohrisch C, Paltiel C, Gelmon K, et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.CrossRefPubMed
4.
Colleoni M, Bonetti M, Coates AS, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000;18:584–90.CrossRefPubMed
5.
Gagliato Dde M, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32:735–44.CrossRefPubMed
6.
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2:322–9.CrossRefPubMedPubMedCentral
7.
Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9–16.CrossRefPubMed
8.
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.CrossRefPubMed
9.
Dragun AE, Pan J, Riley EC, et al. Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol. 2013;36:375–80.CrossRefPubMed
10.
Early AP. SSO-ASTRO consensus guidelines for breast-conserving surgery with whole-breast radiation: in regard to Moran et al. Int J Radiat Oncol Biol Phys. 2014;89:1138–9.CrossRefPubMed
11.
Bodilsen A, Bjerre K, Offersen BV, et al. Importance of margin width in breast-conserving treatment of early breast cancer. J Surg Oncol. 2016;113:609–15.CrossRefPubMed
12.
Reese PP, Yeh H, Thomasson AM, Shults J, Markmann JF. Transplant center volume and outcomes after liver retransplantation. Am J Transplant. 2009;9:309–17.CrossRefPubMed
13.
Guller U, Safford S, Pietrobon R, Heberer M, Oertli D, Jain NB. High hospital volume is associated with better outcomes for breast cancer surgery: analysis of 233,247 patients. World J Surg. 2005;29:994–9; discussion 9–1000.CrossRefPubMed
14.
Hebert-Croteau N, Brisson J, Lemaire J, Latreille J, Pineault R. Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer. Cancer. 2005;104:1343–8.CrossRefPubMed
15.
Komenaka IK, Martinez ME, Pennington RE, Jr., et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst. 2010;102:1178–87.CrossRefPubMed
16.
George P, Chandwani S, Gabel M, et al. Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Women’s Health. 2015;24:209–17.CrossRef
17.
Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110:876–84.CrossRefPubMed
18.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–8.CrossRefPubMed
Metadata
Title
Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?
Authors
Debora de Melo Gagliato, MD
Mariana Chavez-MacGregor, MD, MSc
Publication date
01-07-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6415-8

Other articles of this Issue 7/2018

Annals of Surgical Oncology 7/2018 Go to the issue

Gastrointestinal Oncology

Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer

Breast Oncology

Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy

Hepatobiliary Tumors

Postoperative Adjuvant Trans-Arterial Chemoembolization for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Melanomas

Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?

Gastrointestinal Oncology

The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer

Gastrointestinal Oncology

Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival